1)Takahashi Y and Nishioka K:Survival without tumor shrinkage:re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87:1262-1263, 1995
2)高橋 豊:Tumor Dormancy Therapy癌治療の新たな戦略.医学書院,東京,2000
3)Browder T, Butterfield CE, Kraling BM, et al:Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
4)Klement G, Baruchel S, Rak J, et al:Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
5)細川真澄男:癌細胞の免疫逃避機構.Mebio 13:37-43,1996
6)大森弘之,松村陽右,越智淳三,他:5'-DFURの膀胱癌・前立腺癌に対する臨床第Ⅱ相試験.癌と化学療法 18:2307-2314,1991
7)森 達也,坂田 優,棟方正樹,他:緩和医療における癌化学療法の可能性.癌と化学療法 32:156-160,2005
8)増田富士男,荒井由和,田代和也,他:尿路性器腫瘍に対するUFTの臨床成績.泌尿紀要 30:81-85,1984
9)斉藤典章,山本省一,田中啓幹:進行膀胱癌・前立腺癌に対するFT-207坐剤の臨床効果.西日泌尿 45:195-200,1982
10)中沢速和,合谷信行,大島 直,他:膀胱癌の再発予防,維持療法としてのEtoposide少量長期投与とBestacin併用療法の試み.基礎と臨床 24:723-728,1990
11)Matsuyama H, Yamakawa G, Hirata H, et al:Metastatic urothelial cancer showing an efficacy by low-dose cisplatin. Int J Urol 9:275-277, 2002
12)橋本 博,徳光正行,森川 満,他:進行性尿路上皮癌に対するCisplatin・Etoposide少量連続投与の経験.癌と化学療法 23:941-944,1996
13)Pronzato P, Vigani A, Pensa F, et al:Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol 20:519-521, 1997
14)Bellmunt J, Eres N, Ribas A, et al:Feasibility trial of high-dose 7-day continuous-infuision ifosfamide given on an outpatient basis. Cancer Chemother Pharmacol 40:273-276, 1997
15)Ahmed T, Yagoda A, Needles B, et al:Vinblastine and methotrexate for advanced bladder cancer. J Urol 133:602-604, 1985